Identifying the most at-risk age-group and longitudinal trends of drug allergy labeling amongst 7.3 million individuals in Hong Kong
BMC Medicine · 2024
DOI: 10.1186/s12916-024-03250-0 ↗Kurz gefasst
Fachartikel in der Zeitschrift BMC Medicine, 2024. Verfasst von Valerie Chiang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Immunology, Department of Pathology, Queen Mary Hospital, Pokfulam, Hong Kong. Hauptthemen laut MEDLINE: Hypersensitivity, Drug Hypersensitivity. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health and Medical Research Fund.
Abstract (Originalsprache)
Background
Incorrect drug ‘allergy’ labels remain a global public health concern. Identifying regional trends of drug allergy labeling can guide appropriate public health interventions, but longitudinal or population drug allergy studies remain scarce. We analysed the serial epidemiology of drug allergy labeling to identify specific subgroups at highest risk of drug allergy labeling for potential interventions.
Methods
Longitudinal, population-wide drug allergy labels and clinical data from over 7,337,778 individuals in Hong Kong between 2016 and 2021 were analysed.
Results
The absolute prevalence and incidence of documented drug allergy were 5.61% and 277/100,000 population, respectively. Annual incidence of new allergy labels was stable between 2016 and 2019, until a significant drop in 2020 (−16.3%) during the COVID19 pandemic. The most common allergy labels were anti-infectives (245,832 [44.5%]), non-steroidal anti-inflammatory (106,843 [19.3%]), and nervous system drugs (45,802 [8.3%]). The most common labeled culprits for the most severe immediate-type (anaphylaxis) and non-immediate-type (Stevens-Johnson syndrome) reactions were beta-lactams and nervous system drugs, respectively. For individuals at highest risk of labeling, there was significantly higher incidence of overall drug and beta-lactam allergy labeling amongst individuals aged > 40 years which contributed to the majority of newly labeled allergies (377,004, 68.2%).
Conclusions
Contrary to traditional dogma, we identified disproportionately higher incidence of drug allergy labeling amongst older individuals, rather than the paediatric age group. We advocate for more population-wide drug allergy studies to investigate this phenomenon in other cohorts as well as future preventative and delabeling efforts focusing on the adult population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Immunology, Department of Pathology, Queen Mary Hospital, Pokfulam, Hong Kong.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Pokfulam, Hong Kong.
- Division of Rheumatology and Clinical Immunology, Department of Medicine, Queen Mary Hospital, The University of Hong Kong, 102 Pokfulam Road, Pokfulam, Hong Kong. liphilip@hku.hk.
ORCID-Profile: Philip H Li
Förderung
- Health and Medical Research Fund
Zitieren
APA
Chiang, V., Kan, A. K. C., Saha, C., Au, E. Y. L., & Li, P. H. (2024). Identifying the most at-risk age-group and longitudinal trends of drug allergy labeling amongst 7.3 million individuals in Hong Kong. BMC Medicine. https://doi.org/10.1186/s12916-024-03250-0
Vancouver
Chiang V, Kan AKC, Saha C, Au EYL, Li PH. Identifying the most at-risk age-group and longitudinal trends of drug allergy labeling amongst 7.3 million individuals in Hong Kong. BMC Medicine. 2024. doi:10.1186/s12916-024-03250-0
BibTeX
@article{Chiang2024,
author = {Chiang, Valerie and Kan, Andy Ka Chun and Saha, Chinmoy and Au, Elaine Y L and Li, Philip H},
title = {Identifying the most at-risk age-group and longitudinal trends of drug allergy labeling amongst 7.3 million individuals in Hong Kong},
journal = {BMC Medicine},
year = {2024},
doi = {10.1186/s12916-024-03250-0}
}
EUVIMED